Tianjin Chase Sun Pharmaceutical Co (SZSE:300026) Net Income From Continuing Operations : ¥377 Mil (TTM As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Tianjin Chase Sun Pharmaceutical Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Tianjin Chase Sun Pharmaceutical Co's net income from continuing operations for the three months ended in Mar. 2024 was ¥54 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was ¥377 Mil.

Tianjin Chase Sun Pharmaceutical Co Net Income From Continuing Operations Historical Data

The historical data trend for Tianjin Chase Sun Pharmaceutical Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Chase Sun Pharmaceutical Co Net Income From Continuing Operations Chart

Tianjin Chase Sun Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

408.43

559.68

670.85

621.23

501.57

Tianjin Chase Sun Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															178.79	170.94	162.23	-10.40	54.40

Tianjin Chase Sun Pharmaceutical Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥377 Mil.

Tianjin Chase Sun Pharmaceutical Co (SZSE:300026) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Chase Sun Pharmaceutical Co Ltd (SZSE:300026) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

N/A

Address

No. 20, Quanfa Road, Tianjin Wuqing Development Area, Tianjin, CHN, 301700

Website

http://www.chasesun.cn

Tianjin Chase Sun Pharmaceutical Co Ltd is a high-tech medicine and health industry group. The company offers Chinese herb preparation products, medicinal granules, synthetic drugs, biotech drugs, medical apparatus, and Internet-based therapy.

Executives

Yao Xiao Qing	Director
Chen Rui Qiang	Executives
Li Chun Xu	Executives
Lan Wu Jun	Directors, Directors, and Executives
Zheng Dan	Directors, executives
Zhang Kun	Executives
Gao Guo Wei	Executives
Shang Xiao Mei	Securities Affairs Representative
Sun Zhang Hai	Director
Wu Guang Ning	Supervisors
Wang Long	Executives
Liu Qiang	Supervisors
Ceng Guo Zhuang	Director
Su Bing Jun	Directors, executives
Nie Wei	Supervisors

Tianjin Chase Sun Pharmaceutical Co (SZSE:300026) Headlines

No Headlines